313 related articles for article (PubMed ID: 18326535)
1. Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.
Malesci D; La Montagna G
Rheumatology (Oxford); 2008 May; 47(5):734-5. PubMed ID: 18326535
[No Abstract] [Full Text] [Related]
2. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
Blank N; Max R; Schiller M; Briem S; Lorenz HM
Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
[No Abstract] [Full Text] [Related]
3. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
4. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
5. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
Yazici Y; Erkan D
Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
[No Abstract] [Full Text] [Related]
6. Treatment of rheumatoid arthritis with etanercept.
Genovese MC; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
[TBL] [Abstract][Full Text] [Related]
7. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
Kekow J; Welte T; Kellner U; Pap T
Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
[No Abstract] [Full Text] [Related]
8. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
[No Abstract] [Full Text] [Related]
9. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
10. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis.
Sendur OF; Turan Y; Berkit IK; Tastaban E
Basic Clin Pharmacol Toxicol; 2009 Jun; 104(6):488-90. PubMed ID: 19371261
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
12. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
13. [Etanercept for therapy of rheumatoid arthritis].
Miyasaka N
Nihon Rinsho; 2005 Jan; 63 Suppl 1():521-5. PubMed ID: 15799411
[No Abstract] [Full Text] [Related]
14. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization.
Quartuccio L; De Re V; Fabris M; Marzotto A; Franzolini N; Gasparotto D; Caggiari L; Ferraccioli G; Scott CA; De Vita S
Haematologica; 2006 May; 91(5):691-4. PubMed ID: 16670074
[TBL] [Abstract][Full Text] [Related]
15. Phlegmonous abscess associated with etanercept therapy.
D'Amore M; Minenna G; Favoino E; D'Amore S
Panminerva Med; 2006 Sep; 48(3):199-200. PubMed ID: 17122757
[No Abstract] [Full Text] [Related]
16. Etanercept or infliximab: the patient's considerations.
Sherrick RC
Arch Intern Med; 2006 Jul; 166(13):1418; author reply 1418. PubMed ID: 16832010
[No Abstract] [Full Text] [Related]
17. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos AN; Tiliakos NA
J Rheumatol; 2003 Dec; 30(12):2727. PubMed ID: 14719226
[No Abstract] [Full Text] [Related]
18. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
19. [Etanercept (Enbrel)--our experiences].
Morović-Vergles J; Martinović-Kaliterna D
Reumatizam; 2007; 54(2):69-70. PubMed ID: 18351144
[TBL] [Abstract][Full Text] [Related]
20. Etanercept-associated SLE with lupus nephritis.
Neradová A; Stam F; van den Berg JG; Bax WA
Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
